Search
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L49560] It is the first RSV vaccine approved for use in pregnant patients to prevent RSV in infants.[L49555]
Cinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedA local anesthetic of the amide type now generally used for surface anesthesia. … It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
Mixtures: Scheriproct - SalbeCategories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Anesthetics for Topical UseSetmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigationalSetmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. … [A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate.
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.
Trilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigational[L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016. … Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing
Categories: Detoxifying Agents for Antineoplastic Treatment, MATE 2-K InhibitorsPrademagene zamikeracel
go.drugbank.com/drugs/DB17895ApprovedInvestigational[L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering … [L53008] COL7A1 encodes type VII collagen (C7), which is a major component of anchoring fibrils (AF) that are critical for dermal-epidermal cohesion.
Synonyms: Ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the COL7A1 gene, Ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the human COL7A1 geneCarbenicillin
go.drugbank.com/drugs/DB00578ApprovedIt is susceptible to gastric juice and penicillinase and may damage platelet function.
Synonyms: N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acidCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseRecombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L49560] It is the first RSV vaccine approved for use in pregnant patients to prevent RSV in infants.[L49555]
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively, for the same indication.[L49956,L49966] … [A229278] In February 2021, evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA approval after it was granted approval for the adjunctive treatment of homozygous familial hypercholesterolemia
Sulfadoxine
go.drugbank.com/drugs/DB01299ApprovedInvestigationalWithdrawnA long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.